Pay in 4 interest-free payments of $7.27 Learn more
Ships within 48 hours · Estimated delivery Aug 10 - Aug 15
These reports are relatively rare, but they do exist, and they raise concerns for those who might experience similar symptoms
Tirzepatide: The Dual Agonist Advantage Tirzepatide stands out for its dual agonist effects, combining GLP-1 and GIP (glucose-dependent insulinotropic polypeptide) receptor agonists
These reports help track how people respond to the drug outside of a controlled trial setting, where injection technique, needle size, and other factors may vary more widely
Digestive Support for GLP-1 Treatments: GLP-1 agonists frequently cause digestive side effects, with nausea occurring in 40% of cases, vomiting in 25%, and bowel disturbances in 23%, often leading to treatment discontinuation (Sun F et al., Diabetes Technology & Therapeutics , 2015)
Our findings reveal that tirzepatide attenuates alcohol-induced dopamine signaling, reduces alcohol consumption, and suppresses relapse-like behaviors
Mangoni, A., & Jackson, S
